DK0789766T3 - Kimæriske papillomaviruslignende partikler - Google Patents

Kimæriske papillomaviruslignende partikler

Info

Publication number
DK0789766T3
DK0789766T3 DK95936278T DK95936278T DK0789766T3 DK 0789766 T3 DK0789766 T3 DK 0789766T3 DK 95936278 T DK95936278 T DK 95936278T DK 95936278 T DK95936278 T DK 95936278T DK 0789766 T3 DK0789766 T3 DK 0789766T3
Authority
DK
Denmark
Prior art keywords
particles
papillomavirus
chimeric papillomavirus
useful
chimeric
Prior art date
Application number
DK95936278T
Other languages
English (en)
Inventor
Douglas R Lowy
John T Schiller
Heather Greenstone
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0789766T3 publication Critical patent/DK0789766T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95936278T 1994-10-06 1995-10-06 Kimæriske papillomaviruslignende partikler DK0789766T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/319,467 US5618536A (en) 1992-09-03 1994-10-06 Chimeric papillomavirus-like particles
PCT/US1995/012914 WO1996011274A1 (en) 1994-10-06 1995-10-06 Chimeric papillomavirus-like particles

Publications (1)

Publication Number Publication Date
DK0789766T3 true DK0789766T3 (da) 2004-05-24

Family

ID=23242365

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95936278T DK0789766T3 (da) 1994-10-06 1995-10-06 Kimæriske papillomaviruslignende partikler

Country Status (10)

Country Link
US (2) US5618536A (da)
EP (2) EP0789766B1 (da)
JP (3) JP3343912B2 (da)
AT (1) ATE258985T1 (da)
AU (1) AU3828495A (da)
DE (1) DE69532532T8 (da)
DK (1) DK0789766T3 (da)
ES (1) ES2213754T3 (da)
PT (1) PT789766E (da)
WO (1) WO1996011274A1 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164350A1 (en) * 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
ATE325875T1 (de) * 1994-10-07 2006-06-15 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
US5955087A (en) * 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
DE69734829D1 (de) * 1996-07-17 2006-01-12 Us Health Infektiöse pseudovirale papillomavirus partikel
HUP9904137A3 (en) * 1996-07-29 2001-06-28 Cantab Pharmaceuticals Res Ltd Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
AU781653B2 (en) * 1996-07-30 2005-06-02 Transgene S.A. Pharmaceutical composition for treating papollomavirus tumour and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
WO1998010790A1 (en) * 1996-09-11 1998-03-19 Merck & Co., Inc. Papillomavirus vaccine formulation
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO1998050071A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) * 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) * 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
ES2275350T3 (es) * 1998-08-14 2007-06-01 MERCK & CO., INC. Sistema de administracion de proteinas usando particulas de tipo virus de papilomavirus humano.
US7112330B1 (en) * 1998-08-14 2006-09-26 Chiron Corporation Method for producing yeast expressed HPV types 6 and 16 capsid proteins
US6991795B1 (en) 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
JP4486257B2 (ja) * 1998-10-21 2010-06-23 アメリカ合衆国 自己抗体の誘導のためのウイルス様粒子
US6380364B1 (en) * 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6689366B1 (en) * 1998-12-17 2004-02-10 Merck & Co., Inc. Synthetic virus like particles with heterologous epitopes
WO2000035479A1 (en) * 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
DE19905883C2 (de) * 1999-02-11 2001-05-23 Deutsches Krebsforsch Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
CA2415763A1 (en) * 2000-07-07 2002-01-17 Merck & Co., Inc. Production of chimeric human papillomavirus
GB0018050D0 (en) * 2000-07-21 2000-09-13 Norchip As Detection of human papillomavirus mRNA
US7318928B2 (en) * 2000-08-01 2008-01-15 The Johns Hopkins University Molecular vaccine linking intercellular spreading protein to an antigen
AU2001278117A1 (en) * 2000-08-03 2002-02-18 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US7579007B2 (en) * 2001-02-13 2009-08-25 Jdm Technologies, Inc. Production of “biological carriers” for induction of immune responses and inhibition of viral replication
ATE471990T1 (de) 2001-08-13 2010-07-15 Univ Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
DK1506222T3 (da) * 2002-05-17 2009-07-06 Univ Cape Town Kimæriske, humane papillomavirus16 L1-proteiner omfattende et L2-peptid, viruslignende partikler fremstillet deraf samt en fremgangsmåde til at fremstille partiklerne
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB0228715D0 (en) * 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
EP1732598A4 (en) * 2003-12-31 2009-08-26 Pharmexa Inc INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMAVIRUS USING PEPTIDE COMPOSITIONS AND NUCLEIC ACIDS
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
EP1819835B1 (en) 2004-12-08 2010-08-04 Gen-Probe Incorporated Detection of nucleic acids from multiple types of human papillomaviruses
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
US7314630B2 (en) * 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
CA2595726A1 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
BRPI0607097B8 (pt) * 2005-02-01 2021-05-25 The Gorvernment Of The United States Of America Repres By The Secretary Depart Of Health And Human S uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus
TWI321350B (en) * 2006-04-18 2010-03-01 Advanced Semiconductor Eng Heatsink and heatsink positioning system
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
WO2009055491A2 (en) * 2007-10-22 2009-04-30 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
CN113559253A (zh) * 2007-11-02 2021-10-29 约翰霍普金斯大学 用于治疗或预防人乳头瘤病毒感染的多型hpv肽的组合物和方法
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
PL2444103T3 (pl) 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
WO2018237115A2 (en) 2017-06-23 2018-12-27 Pathovax Llc CHIMERIC VIRUS-LIKE PARTICLES AND THEIR USES AS SPECIFIC REDIRECTORS OF ANTIGENS OF IMMUNE RESPONSES
KR20210110321A (ko) 2018-12-27 2021-09-07 버이뮨 아이엔씨. 접합된 바이러스-유사 입자 및 항-종양 면역 재유도제로서의 이의 용도
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
EP1298211B1 (en) * 1991-07-19 2006-07-12 The University Of Queensland Polynucleotide segment of HPV16 Genome
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins

Also Published As

Publication number Publication date
JP3343912B2 (ja) 2002-11-11
JPH10506796A (ja) 1998-07-07
JP2002053597A (ja) 2002-02-19
US5618536A (en) 1997-04-08
DE69532532T8 (de) 2005-05-25
EP0789766A1 (en) 1997-08-20
ES2213754T3 (es) 2004-09-01
EP1018555A3 (en) 2000-10-11
US5855891A (en) 1999-01-05
DE69532532D1 (de) 2004-03-11
EP0789766B1 (en) 2004-02-04
WO1996011274A1 (en) 1996-04-18
AU3828495A (en) 1996-05-02
ATE258985T1 (de) 2004-02-15
DE69532532T2 (de) 2005-01-05
JP2007143560A (ja) 2007-06-14
EP1018555A2 (en) 2000-07-12
PT789766E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
ATE258985T1 (de) Chimerische papillomavirus-ahnliche partikel
AU6063500A (en) Glycoprotein vi and uses thereof
AU560340B2 (en) Rennin from recombinant dna
EP1159441B8 (en) Delivery of nucleic acids and proteins to cells
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
NL300372I1 (nl) Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen
EP1798239A3 (en) G-protein coupled receptors and uses therefor
EP0804609A4 (en) NEW GENES OF RESPONSE p53
MX26714A (es) Procedimiento para la preparacion de albumina de SUERO HUMANO VECTOR Y PLASMIDO USADOS ASI COMO LEVADURA METILOTROFICA TRANSFORMADA OBTENIDA
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
DE69840413D1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
EP1798287A3 (en) Mammalian cell membrane proteins and related reagents
EP0546074A4 (en) Genetic material encoding igfbp-5
WO2000019988A8 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
EP0990703A4 (en) NEW POLYPEPTIDE, FOR CODING DNA AND THEIR USE
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
AU1141695A (en) Interferon-alpha/beta binding protein, its preparation and use
DE69530261D1 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
WO2001021654A3 (en) Syk kinase-associated cell cycle proteins, compositions and methods of use
WO2001036476A3 (en) Ing2, an iaps associated cell cycle protein, compositions and methods of use
AU6839900A (en) Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence
ATE260339T1 (de) Antikörper gegen menschliches restrictin
WO2000007545A8 (en) Apoptosis proteins